Destiny Pharma plc (LON:DEST – Free Report) shares rose 4.9% on Monday. The company traded as high as GBX4.50 ($0.06) and was last quoted at GBX4.50 ($0.06). About 2,268,629 shares were traded during midday trading, up 222% from its average daily volume of 703,659 shares. The stock had previously closed at GBX4.29 ($0.05).
Analysts set new price targets
Separately, Shore Capital reiterated its “house stock” rating on Destiny Pharma shares in a report on Monday, July 15.
Read our latest report on DEST
Price development of Destiny Pharma
The stock’s 50-day average price is GBX 7.94 and its 200-day average price is GBX 22.01. The company has a market capitalization of £4.31 million, a price-to-earnings ratio of -66.67 and a beta of 0.22.
Insider buying and selling at Destiny Pharma
In other Destiny Pharma news, insider Nigel Rudd acquired 1,240,000 shares of the company’s stock in a transaction that occurred on Friday, August 2. The shares were acquired at an average price of GBX 0.25 ($0.00) per share, for a total transaction of £3,100 ($3,961.66). Company insiders own 25.94% of the company’s stock.
About Destiny Pharma
(Get free report)
Destiny Pharma plc, a biotechnology company, is focused on the discovery, development and commercialization of novel medicines for the prevention of serious infections in the United Kingdom. The Company is involved in the development of NTCD-M3, which is in Phase II clinical trials for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trials for the prevention of post-operative staphylococcal infections; and XF-73 Dermal, which is in preclinical stage for the treatment of skin infections caused by antibiotic-resistant bacteria as well as superficial skin infections caused by antibiotic-resistant bacteria.
More stories
Get daily news and reviews for Destiny Pharma – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Destiny Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.
